Otezla 30 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FA3C9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $84,655
Award facts
- Contract value 100% obligated
- $84,654.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 21, 2026, provides Otezla (apremilast) 30 mg tablets in a quantity of 60 units to the Defense Logistics Agency (DLA) through AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract carries a ceiling value of $84,654.63 and represents a firm fixed-price delivery order with an ultimate completion date of January 22, 2026. No set-aside designation was applied to this award, indicating it was competitively procured on a full and open basis. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as the prime contractor and will fulfill this pharmaceutical supply requirement from its corporate office location in Conshohocken, PA.
This delivery order is executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (IDC SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications across multiple therapeutic domains, vaccines, and medical supplies. The Otezla delivery supports the Defense Health Agency and broader military medical supply chain requirements for immunosuppressive and anti-inflammatory treatments utilized in military treatment facilities and veteran healthcare programs.
Quick answers
Who was awarded contract SPE2DR26FA3C9?
SPE2DR26FA3C9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FA3C9 worth?
The government has obligated $84,655 on SPE2DR26FA3C9.
Is contract SPE2DR26FA3C9 an order under another contract?
Yes. SPE2DR26FA3C9 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA3C9 competed?
The extent of competition for SPE2DR26FA3C9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award